603883 Stock Overview
LBX Pharmacy Chain Joint Stock Company operates pharmacy store chain in China.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 3/6 |
Financial Health | 4/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
LBX Pharmacy Chain Joint Stock Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥30.43 |
52 Week High | CN¥38.95 |
52 Week Low | CN¥22.81 |
Beta | 0.27 |
1 Month Change | -2.62% |
3 Month Change | 5.00% |
1 Year Change | -20.07% |
3 Year Change | -40.99% |
5 Year Change | -6.53% |
Change since IPO | -19.76% |
Recent News & Updates
Recent updates
Shareholder Returns
603883 | CN Consumer Retailing | CN Market | |
---|---|---|---|
7D | -0.2% | 2.6% | 1.9% |
1Y | -20.1% | -20.7% | -11.1% |
Return vs Industry: 603883 matched the CN Consumer Retailing industry which returned -20.7% over the past year.
Return vs Market: 603883 underperformed the CN Market which returned -11.1% over the past year.
Price Volatility
603883 volatility | |
---|---|
603883 Average Weekly Movement | 5.6% |
Consumer Retailing Industry Average Movement | 6.8% |
Market Average Movement | 8.0% |
10% most volatile stocks in CN Market | 11.2% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 603883 has not had significant price volatility in the past 3 months.
Volatility Over Time: 603883's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 35,608 | Li Wang | https://www.lbxdrugs.com |
LBX Pharmacy Chain Joint Stock Company operates pharmacy store chain in China. The company was formerly known as Laobaixing Pharmacy Chain Joint Stock Company. LBX Pharmacy Chain Joint Stock Company was founded in 2001 and is based in Changsha, China.
LBX Pharmacy Chain Joint Stock Company Fundamentals Summary
603883 fundamental statistics | |
---|---|
Market cap | CN¥17.80b |
Earnings (TTM) | CN¥891.90m |
Revenue (TTM) | CN¥22.44b |
19.5x
P/E Ratio0.8x
P/S RatioIs 603883 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603883 income statement (TTM) | |
---|---|
Revenue | CN¥22.44b |
Cost of Revenue | CN¥15.32b |
Gross Profit | CN¥7.12b |
Other Expenses | CN¥6.23b |
Earnings | CN¥891.90m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 30, 2024
Earnings per share (EPS) | 1.52 |
Gross Margin | 31.74% |
Net Profit Margin | 3.97% |
Debt/Equity Ratio | 53.4% |
How did 603883 perform over the long term?
See historical performance and comparison